Join Carol Bognar, Senior Director, as she discusses what can be learned from the recent warning letters regarding clinical practices that have invalidated major trials over the last year. Carol is an experienced regulatory professional with a broad range of Quality Assurance experience, including over 15 years in Clinical Auditing. Join her as she answers the following questions:
Why did one of the largest pharmaceutical companies receive a scathing Warning Letter
from the FDA?
Was there fraud and/or misconduct activity detected by the FDA at one of the
clinical sites?
What should you be doing now to safeguard the integrity of your clinical trials and data?
What lessons can be learned from recent FDA actions?
This complimentary, one-hour, invitation-only webinar is designed for clinical, quality and regulatory professionals to help them understand what actions they should be taking to protect the investments they are making in their clinical trials.
